Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a license for Tetrabenazine in Spain follows a series of launches in key global territories, most notably the US where the product was launched last month and completes the approval process in the major 5 EU territories. The continued worldwide rollout of Tetrabenazine, with new agreements signed in Finland and Taiwan is affirmation of Cambridge's commitment to providing Huntington's disease patients with this important treatment. We are particularly pleased to have partnered in Spain with UCB, one of Europe's leading neurology players."

A spokesperson from UCB said: "Our expertise within the CNS arena will allow us to maximize the value of this potential new therapy for patients, physicians and our shareholders."

Further details in connection with the new licensing deals in Finland and Taiwan and the renewal of existing arrangements in Australia and New Zealand are set out below:

    - In Finland, Cambridge announced that it has granted exclusive rights to
      MediFront to market and distribute Tetrabenazine. Medifront has been
      distributing Tetrabenazine on a named patient basis in Finland for five
      years and will have responsibility for obtaining a marketing
      authorisation in Finland.

    - Cambridge has signed a marketing and distribution agreement with Giddi
      Pharma of Taiwan. Under the terms of the agreement Giddi will have
      exclusive rights to market and distribute Tetrabenazine in that
      territory, and will also be responsible for obtaining a marketing

    - Cambridge has renewed its distribution agreement with its Australian
      partner, Orphan Australia, for the exclusive marketing and distribution
      rights for Tetrabenazine.

    - In New Zealand, Cambridge has renewed its contract with AFT
      Pharmaceuticals, a privately owned company with a focus on the
      Pharmaceutical Rx/OTC market, giving them a further 5 year term with
      Tetrabenazine (marketed as XENAZINE(R)).

About Cambridge Laboratories (Ireland) Limited

Cambridge is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialisation expertise focused on innovative products to treat diseases of the central nervous system. Cambridge has an exciting portfolio of products, both on the market and in development, derived from its proprietary discovery efforts and a carefully constructed network of international partnerships for research, development, sourcing and global commercialisation. Utilising this unusual business model, Cambridge is dedicated to delivering significant value to patients, physicians and partners around the world.

About UCB

UCB, Brussels, Belgium ( is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion Euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).

    For further details:
    Cambridge Laboratories
    Mark Evans, CEO +44-191-296-9369
    David Wildy, CFO +353-1-631-9352
    Financial Dynamics
    Jonathan Birt, John Dineen, +44-20-7831-7193

SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... YORK , June 23, 2016 ... waters, but it continues to present great opportunities to ... companies for today: Intrexon Corp. (NYSE: XON ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ... more about these stocks and receive your complimentary trade ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):